Key Highlights
● Legend Biotech's five-year CARTITUDE-2 Cohort A data showed 50% of 20 patients remained progression-free after one CARVYKTI infusion.
● Median progression-free survival reached 60.5 months, with a five-year overall survival rate of 69.2%.
● Patients had relapsed or refractory multiple myeloma after one to three prior therapy lines, a heavily pretreated population.
● CARVYKTI is co-developed and commercialized with Janssen Biotech, a Johnson & Johnson subsidiary.
Legend Biotech Corp. (NASDAQ:LEGN) filed a Form 6-K on September 25 announcing five-year follow-up data from the CARTITUDE-2 Cohort A study of its cell therapy CARVYKTI, showing that half the patients treated remained alive and progression-free without any further treatment five years after a single infusion. The company frames the results as evidence of the therapy's durability in a hard-to-treat blood cancer.
The Data
According to the press release attached to the filing as Exhibit 99.1, Cohort A of the CARTITUDE-2 study enrolled 20 patients with relapsed or refractory multiple myeloma. At a median follow-up of 60.7 months, 10 of those 20 patients, 50%, remained alive and progression-free without additional therapy following a single infusion of CARVYKTI. Median progression-free survival across the cohort was 60.5 months, and overall survival at five years stood at 69.2%, with median overall survival not yet reached.
The patients in Cohort A had relapsed or refractory multiple myeloma after receiving one to three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, and were refractory to lenalidomide, a heavily pretreated population in which durable remission is uncommon.
What Executives and Investigators Said
Alan Bash, President of CARVYKTI at Legend Biotech, is quoted saying the five-year data, "showing 50% of patients remained alive and progression-free after a single infusion, reinforce the unique curative potential of CARVYKTI." Niels van de Donk, a professor of hematology at Amsterdam UMC, said the findings "show half of patients remain progression- and treatment-free at five years, are unique in multiple myeloma and give us reason for optimism." A patient participant in the study, Joe Rader, is quoted saying, "To be more than five years out from a single treatment and still able to focus on living my life rather than my next therapy is something I never imagined."
About CARVYKTI and the Company
CARVYKTI, known generically as ciltacabtagene autoleucel, is a BCMA-directed, genetically modified autologous T-cell immunotherapy, a CAR-T therapy that reprograms a patient's own immune cells to recognize and destroy myeloma cells expressing the BCMA protein. The therapy was licensed to Janssen Biotech, a Johnson & Johnson subsidiary, in December 2017, and the two companies co-develop and commercialize it. It has received FDA approval for relapsed/refractory multiple myeloma in February 2022 and for second-line use in April 2024, along with authorizations in the European Union, Japan and other markets, and holds breakthrough therapy and Orphan Drug designations in multiple jurisdictions.
Legend Biotech Corp. (NASDAQ:LEGN) describes itself as the largest standalone cell therapy company, with more than 3,000 employees focused on CAR-T therapies and on building what it calls an end-to-end cell therapy platform, working alongside its commercialization partner Johnson & Johnson.
What the Filing Does Not Say
The 6-K and press release do not disclose safety or adverse-event data from the five-year follow-up, nor do they compare these results directly against other approved or investigational therapies in the same patient population. The filing also does not indicate whether Legend Biotech plans any regulatory submissions specifically tied to this five-year dataset.
Next Data and Regulatory Signals
Investors should watch for any regulatory or label updates that reference this long-term follow-up data, as well as additional data readouts from other CARTITUDE cohorts studying CARVYKTI in earlier lines of therapy. Continued collaboration disclosures with Janssen/Johnson & Johnson regarding commercialization progress would also be relevant follow-on filings, as would any future presentation of this data at a medical conference or in a peer-reviewed publication, which the filing does not mention having occurred yet.






Please wait processing your request...